A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer

Journal of Medical Screening

Volumn 10, Issue 3, 2003, Pages 117-122

  Cole, S R ^b,c   Young, G P ^a,c   Esterman, A ^c   Cadd, B ^b   Morcom, J ^b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PEROXIDASE;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIET RESTRICTION; FECES ANALYSIS; FEMALE; GENDER; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NEOPLASM; OCCULT BLOOD; RANDOMIZED CONTROLLED TRIAL; SAMPLING; SCREENING TEST; SOCIAL STATUS;

AGED; AUSTRALIA; COLORECTAL NEOPLASMS; DEMOGRAPHY; DIET; FECES; FEMALE; HEMOGLOBINS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PATIENT COMPLIANCE; PATIENT SELECTION; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 1542360061     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/096914103769011003     Document Type: Article

References (53)

1. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1305-71.
2. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of fecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
3. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
4. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult blood screening on the incidence of colorectal cancer. New Engl J Med 2000;343:1603-7.
5. Greegor DH. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 1967;201:943-5.
6. Greegor DH. Occult blood testing for detection of asymptomatic colon cancer. Cancer 1971;28:131-4.
7. Young GP, Macrae FA, St John DJB. Clinical methods of early detection: basis, use and evaluation. In: Young GP, Levin B, Rozen P, eds. Prevention and early detection of colorectal cancer. London: WB Saunders, 1990:241-70.
8. Jaffe RM, Kasten B, Young DS, et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975;83:824-6.
9. Macrae FA, St John DJB, Caligiore P, et al. Optimal dietary conditions for Hemoccult testing. Gastroenterology 1982;82:899-903.
10. Simon JB. Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 1985;88:820-37.
11. Young GP, St John DJB. Faecal occult blood tests: Choice, usage and clinical applications. Clin Biochem Rev 1992;13:161-7.
12. Young GP, St John DJB, Winawer SJ, et al. Choice of fecal occult blood tests for colorectal cancer screening: Recommendations based on performance characteristics in population studies. Am J Gastroenterol, 2002;97:2499-507.
13. Adams EC, Layman KM. Immunochemical confirmation of gastrointestinal bleeding. Ann Clin Lab Sci 1974;4:343-9.
14. Barrows GH, Burton RM, Jarrett DD, et al. Immunochemical detection of human blood in faeces. Am J Clin Path 1978;69:342-6.
15. Saito H, Tsuchida S, Fukushi M, et al. An immunological occult blood test for mass screening of colorectal cancer by reverse passive hemagglutination (RPHA). Jap J Gastroenterol 1984;81:2831-3.
16. St John DJB, Young GP. Is there a need to restrict diet in occult blood screening for colorectal cancer? Gastroenterology 1992;102:A402.
17. Adlercreutz H, Partanen P, Virkola P, et al. Five guaiac-based tests for occult blood in faeces compared in vitro and in vivo. Scand J Clin Lab Invest 1984;44:519-28.
18. Young GP, St John DJB. Selecting an occult blood test for use as a screening tool for large bowel cancer. Front Gastrointest Res 1991;18:135-56.
19. McDonald CA, Burford Y, Yuen AC, et al. Immunochemical detection of faecal occult blood. Aust N Z J Med 1984;14:105-10.
20. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult blood tests for colorectal cancer screening. N Engl J Med 1990:334:154-9.
21. Hardcastle JD, Thomas WM, Chamberlain J, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for the first 107,349 subjects. Lancet 1989;1(8648):1160-4.
22. St John DJB, Young GP, Alexeyeff MA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993;104:1661-8.
23. King J, Fairbrother G, Thompson C, et al. Colorectal cancer screening: optimal compliance with postal faecal blood test. Aust N Z J Surg 1992;62:714-9.
24. Joseph A. Compliance with fecal occult blood testing: the role of restrictive diets. Am J Public Health 1988;78:839-41.
25. Robinson MHE, Pye G, Thomas WM, et al. Haemoccult screening for colorectal cancer: the effect of dietary restriction on compliance. Europ J Surg Oncol 1994;20:545-8.
26. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001;175:195-8.
27. Vernon S. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997;89:1406-22.
28. Ahlquist DA, Schwartz S, Isaacson J, et al. A stool collection device: the first step in occult blood testing. Ann Int Med 1988;108:609-12.
29. Nakama H, Fattah A, Zhang B, et al. A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps. Hepato-Gastroenterol 2000;47:386-9.
30. Nakama H, Kamijo N, Miyata K, et al. Sensitivity and specificity of several immunochemical tests for colorectal cancer. Hepato-Gastroenterol 1998;45:1579-82.
31. Myers RE, Vernon SW, Tilley BC, et al. Intention to screen for colorectal cancer among white male employees. Prev Med 1998;27:279-87.
32. Frew E, Wolstenholme J, Whynes D. Mass population screening for colorectal cancer: factors influencing subjects' choice of screening test. J Health Serv Res Policy 2001;6:85-91.
33. Friedman LC, Everett TE, Peterson L, et al. Compliance with fecal occult blood test screening among low-income medical outpatients: a randomized controlled trial using a videotaped intervention. J Cancer Educ 2001;16:85-8.
34. Weinrich SP, Weinrich MC, Atwood J, et al. Predictors of fecal occult blood screening among older socioeconomically disadvantaged Americans: a replication study. Patient Educ Couns 1998;34:103-14.
35. Li T, Nakama H, Wei N. Reasons for non-compliance in colorectal cancer screening with fecal occult blood test. Eur J Med Res 1998;3:397-400.
36. Tazi MA, Faivre J, Dassonville F, et al. Participation in faecal occult blood screening for colorectal cancer in a well defined French population: results of five screening rounds from 1988 to 1996. J Med Screen 1997;4:147-51.
37. Grazzini G, Castiglione G, Isu A, et al. Colorectal cancer screening by fecal occult blood testing: results of a population-based experience. Tumori 2000;86:3 84-8.
38. Mandelson MT, Curry SJ, Anderson LA, et al. Colorectal cancer screening participation by older women. Am J Prev Med 2000;19:149-54.
39. Weller DP, Owen N, Hiller JE, et al. Colorectal cancer and its prevention: prevalence of beliefs, attitudes, intentions and behaviour. Aust J Pub Health 1995;19:19-23.
40. Tong S, Hughes K, Oldenburg B, et al. Socio-demographic correlates of screening intention for colorectal cancer. Aust N Z J Pub Health 2000;24:610-4.
41. Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-61.
42. Australian Bureau of Statistics. Census of population and housing: socioeconomic indexes for areas (SEIFA), South Australia 2033.4.30.001. Available at http://www.abs.gov.au/austats/ (last accessed October 2002).
43. Cockburn J, Paul C, Tzelepis F, et al. Screening for bowel cancer among NSW adults with varying levels of risk: a community survey. Aust N Z J Pub Health 2002;26:236-41.
44. Rozen P, Knaani J, Samuel Z. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test within an endoscopy study. Cancer 2000;89:46-52.
45. Sinatra MA, St John DJB, Young GP. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Clin Chem 1999;45:123-6.
46. Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Dig Dis Sci 1999;44:756-60.
47. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. BMJ 1986;292:746-50.
48. Young GP, Rozen P, Levin B. How should we screen for early colorectal neoplasia? In: Rozen P, Young GP, Levin B, et al., eds. Colorectal cancer in clinical practice: prevention & early detection. London: Isis Publications, 2002:77-99.
49. Lynch NM, McHutchison JG, Young GP, et al. Gastrointestinal blood loss from a new buffered aspirin (Ostoprin): measurement by radiochromium and HemoQuant™ techniques. Aust N Z J Med 1989;19:89-96.
50. Pignone M, Campbell MK, Carr C, et al. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001;4:150-6.
51. Cole SR, Young GP, Byrne D, et al. Participation in faecal occult blood test-based screening for colorectal cancer is improved by endorsement by the primary care practitioner. J Med Screen 2002;9:147-52.
52. Sutton S, Wardle J, Taylor T, et al. Predictors of attendance in the UK flexible sigmoidoscopy screening trial. J Med Screen 2000;7:99-104.
53. Herold AH, Riker AI, Warner EA, et al. Evidence of gender bias in patients undergoing flexible sigmoidoscopy. Cancer Detect Prevent 1997;21:141-7.